Inocras Unveils ASCO 2026 Findings on Whole-Genome HRD Phenotyping to Predict PARP Inhibitor Response in Ovarian Cancer
Inocras Presents Real-World Evidence Supporting Whole-Genome HRD Profiling in Ovarian Cancer Treatment Inocras, a bioinformatics-driven precision oncology company specializing in whole-genome sequencing and advanced genomic analytics, has announced that new…
Agios Secures EU Approval for PYRUKYND® (Mitapivat) to Treat Adults with Thalassaemia, Announces Avanzanite Bioscience
Agios Secures EU Approval for PYRUKYND® (mitapivat) to Treat Adults Living with Thalassaemia, Announces Avanzanite Bioscience Avanzanite Bioscience B.V. has announced a major milestone in the treatment of rare blood…
BeOne Medicines Highlights Oncology Leadership at ASCO and EHA 2026 with More Than 60 Abstract Presentations
BeOne Medicines Showcases Expanding Oncology Pipeline With More Than 60 Presentations at ASCO and EHA 2026 BeOne Medicines Ltd. has announced a major presence at two of the world’s leading…
Baszucki Group Supports Oxford University Clinical Trial Exploring Ketogenic Therapy for Early Psychosis
Baszucki Group Backs Oxford University Trial Exploring Ketogenic Therapy for Early Psychosis Baszucki Group has announced a £1.17 million grant to support a pioneering clinical trial at the University of…
Datroway® Wins U.S. Approval as First TROP2 ADC for First-Line Metastatic TNBC Treatment
Datroway Gains Landmark U.S. Approval for First-Line Treatment of Metastatic Triple-Negative Breast Cancer In a major advancement for breast cancer treatment, Daiichi Sankyo and AstraZeneca have announced that the U.S.…
ClearNote Health to Showcase Avantect® Pancreatic Cancer Test Data at 2026 ASCO Meeting
ClearNote Health to Present New Validation Data for Avantect Pancreatic Cancer Test at ASCO 2026 ClearNote Health has announced that it will present new multi-cohort validation data for its Avantect…
Enhertu® Receives CHMP Backing for EU Approval in Previously Treated HER2-Positive Metastatic Solid Tumors
Enhertu® Receives CHMP Recommendation for EU Approval in HER2-Positive Metastatic Solid Tumors Enhertu has received a positive recommendation for approval in the European Union from the Committee for Medicinal Products…
Henry Schein Elects William K. “Dan” Daniel as Independent Board Chairman
Henry Schein Appoints Dan Daniel as Independent Chairman Following Stanley Bergman’s Retirement Henry Schein has announced a major leadership transition as its Board of Directors elected William K. “Dan” Daniel…
Merck Gains CHMP Support for KEYTRUDA® Plus Padcev® in Muscle-Invasive Bladder Cancer
Merck Secures CHMP Support for KEYTRUDA® Plus Padcev® in Muscle-Invasive Bladder Cancer Merck, known as MSD outside the United States and Canada, has announced that the Committee for Medicinal Products…
Gilead Wins CHMP Backing for Trodelvy in First-Line Metastatic TNBC
Gilead Wins CHMP Backing for Trodelvy® in First-Line Metastatic TNBC Treatment Gilead Sciences has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency…
ImmunityBio Shares ISPOR 2026 Survey on Bladder Preservation Preference in UK NMIBC Patients
ImmunityBio Survey Highlights Diverse Treatment Priorities Among Patients With BCG-Unresponsive NMIBC ImmunityBio has unveiled new patient survey findings that shed light on how individuals living with Bacillus Calmette–Guérin (BCG)-unresponsive high-risk…
OPTIMA Trial Data Presented at ASCO Support Prosigna-Guided Chemotherapy Decision-Making in Breast Cancer
Veracyte to Present Practice-Changing Oncology Data at ASCO 2026 Highlighting Advances in Breast and Prostate Cancer Genomic Testing Veracyte announced that major new clinical data involving its Prosigna Breast and…